噬菌体疗法市场规模、份额、成长分析（按产品、类型、适应症、最终用户和地区）- 2025 年至 2032 年产业预测

2023 年全球噬菌体疗法市场规模为 2,980 万美元，预计将从 2024 年的 3,499 万美元成长到 2032 年的 1.2625 亿美元，预测期内（2025-2032 年）的复合年增长率为 17.4%。

为了应对日益严重的抗生素抗药性威胁，全球噬菌体治疗市场正在迅速发展，这是一个迫切的公共卫生问题。推动成长的因素包括多重抗药性感染疾病的增加、对替代抗菌疗法的投资增加以及公共和私营部门加强研发力度。噬菌体疗法因其对病原体的高度特异性、对正常微生物群的保存以及最小的副作用而成为一种有吸引力的治疗选择。政府倡议正在进一步刺激创新，尤其是在北美和欧洲。然而，监管的不确定性、有限的临床证据和后勤挑战继续阻碍其广泛采用。然而，基因组定序和个人化医疗的进步可能会克服这些障碍，预示着噬菌体疗法在对抗超级细菌和重塑感染疾病治疗方面有着光明的前景。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 技术进步
• 案例研究
• 专利分析

噬菌体治疗市场规模（按产品和复合年增长率） (2025-2032)

• 市场概览
• 大肠桿菌
• 金黄色葡萄球菌
• 沙门氏菌
• 铜绿假单胞菌
• 其他的

噬菌体治疗市场规模（按类型及复合年增长率） (2025-2032)

• 市场概览
• 双股DNA噬菌体
• SsDNA噬菌体
• SsRNA噬菌体
• 其他的

噬菌体疗法市场规模（按适应症和复合年增长率） (2025-2032)

• 市场概览
• 尿道感染
• 慢性中耳炎
• 慢性溃疡性大肠炎
• 骨感染疾病
• 伤口/皮肤感染疾病
• 囊肿纤维化
• 其他适应症

噬菌体治疗市场规模（依最终用户和复合年增长率） (2025-2032)

• 市场概览
• 医院和诊所
• 研究和学术机构
• 其他的

噬菌体治疗市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Armata Pharmaceuticals（United States）
• BiomX Inc.（Israel）
• Intralytix（United States）
• Locus Biosciences（United States）
• Amplify Biosciences（United States）
• EnBiotix（United States）
• PhagoMed Biopharma（Austria）
• Transgene SA（France）
• Imugene Ltd（Australia）
• Evotec SE（Germany）
• Novolytics（United Kingdom）
• GangaGen Biotechnologies（India）
• Pherecydes Pharma（France）
• Eligo Bioscience（France）
• Micreos（Netherlands）
• ContraFect Corporation（United States）
• Phagomed Biopharma GmbH（Austria）
• PhagePro Inc.（United States）
• TechnoPhage（Portugal）
• Intralytix, Inc.（United States）

结论和建议

Global Phage Therapy Market size was valued at USD 29.8 million in 2023 and is poised to grow from USD 34.99 million in 2024 to USD 126.25 million by 2032, growing at a CAGR of 17.4% during the forecast period (2025-2032).

The global Phage Therapy Market is rapidly gaining traction in response to the escalating threat of antibiotic resistance, a pressing public health issue. Growth drivers include the rise of multidrug-resistant infections, increased investments in alternative antimicrobial therapies, and enhanced R&D efforts from both public and private sectors. Phage therapy offers high specificity against pathogens, maintains the normal microbiome, and has minimal side effects, making it an attractive treatment option. Government initiatives, particularly in North America and Europe, further stimulate innovation. However, regulatory uncertainties, limited clinical evidence, and logistical challenges hinder widespread adoption. Yet, advancements in genome sequencing and personalized medicine may overcome these barriers, signaling a promising future for phage therapy in combating superbugs and reshaping anti-infective treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Phage Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Phage Therapy Market Segments Analysis

Global Phage Therapy Market is segmented by Product, Type, Disease Indication, End User and region. Based on Product, the market is segmented into Escherichia coli, Staphylococcus aureus, Salmonella, Pseudomonas aeruginosa and Others. Based on Type, the market is segmented into DsDNA Bacteriophage, SsDNA Bacteriophage, SsRNA Bacteriophage and Others. Based on Disease Indication, the market is segmented into Urinary Tract Infections, Chronic Otitis, Chronic Ulcerative Colitis, Bone Infection, Wound and Skin Infections, Cystic Fibrosis and Other Disease Indications. Based on End User, the market is segmented into Hospital & Clinics, Research & Academic Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Phage Therapy Market

The global phage therapy market is primarily driven by the rising threat of antimicrobial resistance (AMR), which occurs when bacteria evolve to resist antibiotics, complicating the treatment of infections. The misuse and overprescription of these medications have led to a significant rise in AMR cases, resulting in increased mortality rates, the spread of diseases, and escalating healthcare expenses. The World Health Organization projects that by 2050, AMR could cause up to 10 million deaths annually. As such, there is a growing need for alternative treatments like phage therapy to address these challenges and manage the increasing prevalence of chronic infections.

Restraints in the Global Phage Therapy Market

One of the primary obstacles facing the global phage therapy market is the insufficient clinical evidence supporting its efficacy and safety. Currently, most available research is limited to small-scale studies or compassionate use cases, which often lack the rigorous testing found in large randomized controlled trials. This deficiency undermines the confidence of healthcare professionals and regulatory bodies in phage treatments. Consequently, this skepticism hampers efforts to gain regulatory approval, establish acceptance among practitioners, and scale the therapy for broader use. As a result, the commercial introduction of phage therapy and its integration into standard treatment protocols are significantly hindered.

Market Trends of the Global Phage Therapy Market

The Global Phage Therapy market is witnessing a significant trend towards the integration of artificial intelligence and bioinformatics, revolutionizing treatment specificity and efficacy. As developers increasingly utilize AI-assisted phage-host prediction programs and automated screening platforms, the acceleration of phage selection and development is becoming more efficient and cost-effective. This technological innovation not only reduces development timelines but also enhances therapeutic precision, making phage therapy a promising component of personalized medicine. As a result, the market is poised for substantial growth, reflecting the rising demand for targeted treatments in the face of antibiotic resistance and complex infectious diseases.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Case Studies
• Patent Analysis

Global Phage Therapy Market Size by Product & CAGR (2025-2032)

• Market Overview
• Escherichia coli
• Staphylococcus aureus
• Salmonella
• Pseudomonas aeruginosa
• Others

Global Phage Therapy Market Size by Type & CAGR (2025-2032)

• Market Overview
• DsDNA Bacteriophage
• SsDNA Bacteriophage
• SsRNA Bacteriophage
• Others

Global Phage Therapy Market Size by Disease Indication & CAGR (2025-2032)

• Market Overview
• Urinary Tract Infections
• Chronic Otitis
• Chronic Ulcerative Colitis
• Bone Infection
• Wound and Skin Infections
• Cystic Fibrosis
• Other Disease Indications

Global Phage Therapy Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospital & Clinics
• Research & Academic Institutes
• Others

Global Phage Therapy Market Size & CAGR (2025-2032)

• North America (Product, Type, Disease Indication, End User)
  • US
  • Canada
• Europe (Product, Type, Disease Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Type, Disease Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Type, Disease Indication, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Type, Disease Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Armata Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BiomX Inc. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intralytix (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Locus Biosciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amplify Biosciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EnBiotix (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PhagoMed Biopharma (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Transgene S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Imugene Ltd (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evotec SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novolytics (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GangaGen Biotechnologies (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pherecydes Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eligo Bioscience (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Micreos (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ContraFect Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phagomed Biopharma GmbH (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PhagePro Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TechnoPhage (Portugal)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intralytix, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations